Generating anti-infective agents to treat RSV & Aspergillus




Imperial College London

Investment stage

Post-Series A

Pulmocide is generating a pipeline of novel, potent first-in-class anti-infective agents for delivery by inhaled administration for the treatment of life-threatening lower respiratory tract viral and fungal infections.

Unlike currently available treatments for fungal and viral infections in the lung, Pulmocide’s innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.

The Pulmocide team has an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications. The team has particular expertise in the identification of compounds with optimal characteristics for lung delivery.

Related news

View all news